Natera Partners With One Lambda to Distribute Kidney Transplant Rejection Test

Feb 01, 2019

NEW YORK (GenomeWeb) – Natera said today that it has struck a distribution deal with Thermo Fisher Scientific's One Lamda to co-distribute its cell-free DNA-based kidney transplant rejection test in the US.

Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in a statement that Natera's cfDNA test "complements [its] existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Effective Miniaturization of Illumina Nextera XT Library Prep for Multiplexed Whole Genome Sequencing and Microbiome Applications

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu